SNP MSP Aileen McLeod asked the Scottish government how value-based pricing will impact on the availability of orphan and ultra-orphan medicines such as Kalydeco, during topical questions on 15 January 2013.
Health Secretary Alex Neil said pricing of medicines was a reserved matter and negotiations on value-based pricing were ongoing.
Mr Neil said, in the meantime, work was underway to develop a £21m fund to help improve access to treatment for people with rare medical conditions.
He said the fund would "cover the cost of successful individual patient treatment requests for high cost low volume orphan medicines which have not been recommended for routine use by the Scottish Medicines Consortium, such as Kalydeco".
The £21m is available from March through to April next year and will help cover the cost of successful requests under the IPTR system.
Kalydeco - also known as ivacaftor - was rejected for use in Scotland by the SMC on Monday largely on the grounds of cost.
Labour MSP Iain Gray asked Enterprise Minister Fergus Ewing what steps the government was taking to support the workforce of Montgomery Litho Ltd following its liquidation.